AI Engines For more Details: Perplexity Kagi Labs You
Antiplatelet Effects: Picotamide inhibits platelet aggregation, which is the process by which platelets clump together to form blood clots. By preventing excessive platelet aggregation, picotamide helps reduce the risk of thrombosis, which can lead to conditions such as myocardial infarction (heart attack) or stroke.
Cardiovascular Protection: Picotamide's antiplatelet effects contribute to its role in cardiovascular protection. It may be used in the management of conditions such as coronary artery disease, peripheral artery disease, and cerebrovascular disease to prevent thrombotic events and improve blood flow.
Peripheral Vascular Disease: Picotamide may benefit individuals with peripheral vascular disease (PVD), a condition characterized by narrowing or blockage of the blood vessels outside the heart and brain. By improving blood flow and reducing the risk of blood clots, picotamide can help alleviate symptoms associated with PVD, such as intermittent claudication (leg pain during exercise) and promote wound healing.
Intermittent Claudication: Intermittent claudication is a symptom of peripheral arterial disease characterized by pain or cramping in the legs during physical activity due to inadequate blood flow. Picotamide's ability to improve blood flow and inhibit platelet aggregation may help relieve symptoms and increase exercise tolerance in individuals with intermittent claudication.
Stroke Prevention: As a platelet aggregation inhibitor, picotamide may also play a role in stroke prevention, particularly in individuals at high risk of ischemic stroke. By reducing the formation of blood clots in cerebral arteries, picotamide may help prevent thrombotic strokes, which occur when a blood clot blocks blood flow to the brain.
Side Effects: Common side effects associated with picotamide may include gastrointestinal disturbances such as dyspepsia (indigestion), nausea, vomiting, or diarrhea. It may also cause bleeding disorders or bruising, particularly in individuals predisposed to bleeding or those taking other anticoagulant medications.
Drug Interactions: Picotamide may interact with other medications, particularly other antiplatelet agents or anticoagulants, increasing the risk of bleeding. Concurrent use of picotamide with nonsteroidal anti-inflammatory drugs (NSAIDs) or selective serotonin reuptake inhibitors (SSRIs) may also increase the risk of gastrointestinal bleeding.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3 | 0.3 | 9 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 2.6 | 2 | 0.3 |
| Allergies | 3.7 | 2.1 | 0.76 |
| Allergy to milk products | 1.5 | 1.2 | 0.25 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 3.4 | 4.4 | -0.29 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 0.5 | 2.6 |
| Ankylosing spondylitis | 3.1 | 1.1 | 1.82 |
| Anorexia Nervosa | 1.2 | 2.2 | -0.83 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 3.5 | 2.2 | 0.59 |
| Atherosclerosis | 1.7 | 0.9 | 0.89 |
| Atrial fibrillation | 2.8 | 1.4 | 1 |
| Autism | 5.8 | 5.5 | 0.05 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.6 | 1.6 | |
| Bipolar Disorder | 1.4 | 1.4 | 0 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.6 | 2 | -2.33 |
| Carcinoma | 3.2 | 1.9 | 0.68 |
| Celiac Disease | 1.4 | 2.1 | -0.5 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 2.8 | 3.6 | -0.29 |
| Chronic Kidney Disease | 3.1 | 1.3 | 1.38 |
| Chronic Lyme | 0.3 | 0.8 | -1.67 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 1.7 | 0.18 |
| Chronic Urticaria (Hives) | 1.5 | 0.3 | 4 |
| Coagulation / Micro clot triggering bacteria | 1 | 1.3 | -0.3 |
| Cognitive Function | 2 | 1.3 | 0.54 |
| Colorectal Cancer | 4.7 | 2.3 | 1.04 |
| Constipation | 1.3 | 0.7 | 0.86 |
| Coronary artery disease | 2.1 | 1.7 | 0.24 |
| COVID-19 | 4.9 | 6.3 | -0.29 |
| Crohn's Disease | 5.1 | 3.2 | 0.59 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 0.7 | 1.8 | -1.57 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 1.3 | 1.4 | -0.08 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 6.4 | 5.3 | 0.21 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 1.5 | 0.2 |
| Endometriosis | 2.6 | 1.6 | 0.63 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.7 | 0.7 | 2.86 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 1.9 | 1.4 | 0.36 |
| Functional constipation / chronic idiopathic constipation | 3.2 | 2.9 | 0.1 |
| gallstone disease (gsd) | 2.5 | 1.1 | 1.27 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.4 | 1.25 |
| Generalized anxiety disorder | 2.2 | 1.6 | 0.38 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.6 | 0.5 | 2.2 |
| Graves' disease | 1.5 | 3.3 | -1.2 |
| Gulf War Syndrome | 0.9 | 0.5 | 0.8 |
| Halitosis | 1.3 | 0.3 | 3.33 |
| Hashimoto's thyroiditis | 2.9 | 0.7 | 3.14 |
| Heart Failure | 2.7 | 1.3 | 1.08 |
| hemorrhagic stroke | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.2 | 0.6 | 1 |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
| hyperglycemia | 1.3 | 0.7 | 0.86 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.8 | 3.1 | -0.11 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 2.4 | 0.3 | 7 |
| IgA nephropathy (IgAN) | 1.2 | 2.4 | -1 |
| Inflammatory Bowel Disease | 4.3 | 4.9 | -0.14 |
| Insomnia | 2 | 2.1 | -0.05 |
| Intelligence | 0.9 | 0.2 | 3.5 |
| Intracranial aneurysms | 1 | 0.6 | 0.67 |
| Irritable Bowel Syndrome | 5.3 | 3.1 | 0.71 |
| ischemic stroke | 2 | 1.7 | 0.18 |
| Liver Cirrhosis | 5.1 | 3.5 | 0.46 |
| Long COVID | 4.3 | 4.4 | -0.02 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.1 | 1 | 0.1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1 | 0.9 | 0.11 |
| ME/CFS with IBS | 0.6 | 1.7 | -1.83 |
| ME/CFS without IBS | 0.7 | 1.7 | -1.43 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.3 | 0.5 | 1.6 |
| Metabolic Syndrome | 5.1 | 4.9 | 0.04 |
| Mood Disorders | 6.2 | 4.6 | 0.35 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.1 | 6 |
| Multiple Sclerosis | 4.1 | 3.5 | 0.17 |
| Multiple system atrophy (MSA) | 0.5 | 0.7 | -0.4 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 1.2 | -1.2 | |
| Neuropathy (all types) | 0.4 | 1.1 | -1.75 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.1 | 2.8 | 0.46 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 6.2 | 5.1 | 0.22 |
| obsessive-compulsive disorder | 2.6 | 2.6 | 0 |
| Osteoarthritis | 1.8 | 1.2 | 0.5 |
| Osteoporosis | 2.2 | 1.3 | 0.69 |
| pancreatic cancer | 0.4 | 0.3 | 0.33 |
| Parkinson's Disease | 3.8 | 5 | -0.32 |
| Polycystic ovary syndrome | 3.8 | 2.1 | 0.81 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2.3 | 1.2 | 0.92 |
| Psoriasis | 2.4 | 1.3 | 0.85 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5 | 3.4 | 0.47 |
| Rosacea | 0.7 | 0.7 | 0 |
| Schizophrenia | 4.1 | 2.3 | 0.78 |
| scoliosis | 0.4 | 0.3 | 0.33 |
| Sjögren syndrome | 1.9 | 2.1 | -0.11 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.2 | 8 |
| Stress / posttraumatic stress disorder | 2.3 | 1.7 | 0.35 |
| Systemic Lupus Erythematosus | 2.7 | 1.3 | 1.08 |
| Tic Disorder | 0.7 | 1.3 | -0.86 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.8 | 3.2 | -0.14 |
| Type 2 Diabetes | 5.7 | 4.9 | 0.16 |
| Ulcerative colitis | 3.6 | 3 | 0.2 |
| Unhealthy Ageing | 3 | 1.2 | 1.5 |
| Vitiligo | 1.3 | 0.9 | 0.44 |
